(News Bulletin 247) – TheraVet rose on the Paris Stock Exchange on Wednesday following the announcement of the commercial launch in Europe and the United Kingdom of a first bone substitute with prolonged release of antibiotics.
The veterinary biotechnology company explains that the product, called ‘Biocera-Vet Combo-Clean’, makes it possible to locally provide a high concentration of antibiotics while ensuring the stability of the system thanks to its mechanical resistance.
Bone infections are often a major problem during orthopedic surgeries and can occur in 5% of operations, explains the Walloon company in a press release.
The bone substitute – which can be mixed with the seven most commonly used antibiotics for bone infections – displays a long-lasting action, likely to last up to 30 days.
This marketing – which reinforces the ‘Biocera-Vet’ range – was well received on the stock market since the TheraVet share gained more than 4% at the end of the morning. The title still yields 13% since the beginning of the year.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
